Lucid Diagnostics Inc. (LUCD)
Lucid Diagnostics Statistics
Share Statistics
Lucid Diagnostics has 83.64M shares outstanding. The number of shares has increased by 23% in one year.
| Shares Outstanding | 83.64M |
| Shares Change (YoY) | 23% |
| Shares Change (QoQ) | 9.91% |
| Owned by Institutions (%) | 6.57% |
| Shares Floating | 31.75M |
| Failed to Deliver (FTD) Shares | 22.3K |
| FTD / Avg. Volume | 3.81% |
Short Selling Information
The latest short interest is 542.01K, so 0.91% of the outstanding shares have been sold short.
| Short Interest | 542.01K |
| Short % of Shares Out | 0.91% |
| Short % of Float | 2.22% |
| Short Ratio (days to cover) | 1.65 |
Valuation Ratios
The PE ratio is -1.12 and the forward PE ratio is -1.73. Lucid Diagnostics's PEG ratio is 0.06.
| PE Ratio | -1.12 |
| Forward PE | -1.73 |
| PS Ratio | 24.25 |
| Forward PS | 2.6 |
| PB Ratio | -25.48 |
| P/FCF Ratio | -1.78 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Lucid Diagnostics Inc. has an Enterprise Value (EV) of 55.24M.
| EV / Earnings | -1.05 |
| EV / Sales | 22.75 |
| EV / EBITDA | -1.11 |
| EV / EBIT | -1.14 |
| EV / FCF | -1.67 |
Financial Position
The company has a current ratio of 0.75, with a Debt / Equity ratio of -6.6.
| Current Ratio | 0.75 |
| Quick Ratio | 0.74 |
| Debt / Equity | -6.6 |
| Total Debt / Capitalization | 117.85 |
| Cash Flow / Debt | -2.15 |
| Interest Coverage | -116.54 |
Financial Efficiency
Return on equity (ROE) is 22.79% and return on capital (ROIC) is -374.55%.
| Return on Equity (ROE) | 22.79% |
| Return on Assets (ROA) | -1.93% |
| Return on Capital (ROIC) | -374.55% |
| Revenue Per Employee | $34,685.71 |
| Profits Per Employee | $-752,371.43 |
| Employee Count | 70 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 30.5 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 42.2% in the last 52 weeks. The beta is 1.34, so Lucid Diagnostics's price volatility has been higher than the market average.
| Beta | 1.34 |
| 52-Week Price Change | 42.2% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 0.93 |
| Relative Strength Index (RSI) | 60.16 |
| Average Volume (20 Days) | 585.18K |
Income Statement
In the last 12 months, Lucid Diagnostics had revenue of 2.43M and earned -52.67M in profits. Earnings per share was -1.26.
| Revenue | 2.43M |
| Gross Profit | -6.05M |
| Operating Income | -48.48M |
| Net Income | -52.67M |
| EBITDA | -49.75M |
| EBIT | -48.48M |
| Earnings Per Share (EPS) | -1.26 |
Balance Sheet
The company has 18.9M in cash and 15.26M in debt, giving a net cash position of 3.64M.
| Cash & Cash Equivalents | 18.9M |
| Total Debt | 15.26M |
| Net Cash | 3.64M |
| Retained Earnings | -150.74M |
| Total Assets | 22.6M |
| Working Capital | 2.58M |
Cash Flow
In the last 12 months, operating cash flow was -32.82M and capital expenditures -221K, giving a free cash flow of -33.04M.
| Operating Cash Flow | -32.82M |
| Capital Expenditures | -221K |
| Free Cash Flow | -33.04M |
| FCF Per Share | -0.79 |
Margins
Gross margin is -249.18%, with operating and profit margins of -2K% and -2.17K%.
| Gross Margin | -249.18% |
| Operating Margin | -2K% |
| Pretax Margin | -2.17K% |
| Profit Margin | -2.17K% |
| EBITDA Margin | -2.05K% |
| EBIT Margin | -2K% |
| FCF Margin | -1.36K% |
Dividends & Yields
LUCD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -81.29% |
| FCF Yield | -25.47% |
Analyst Forecast
The average price target for LUCD is $2.5, which is 61.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.5 |
| Price Target Difference | 61.3% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -13.28 |
| Piotroski F-Score | 4 |